At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness of Colchicine Among Patients With COVID-19 Infection
In Brief
A Phase 2 clinical trial evaluating Colchicine 0.5 MG and usual care treatment for Coronavirus Infection. Completed, enrolled 100 participants across 1 site.
Detailed Summary
In November 2019, there were a lot of cases of an acute respiratory illness (then named at February 11th as COVID\_19) which first case was reported in Wuhan, China,The SARS COV-2 had been spread in a fast way to involve whole world, As it's obvious that Colchicine is a drug that is most commonly and widely used to treat and prevent acute attacks of Gout, other crystal induced arthropathy,colchicine has important role in inhibiting activation of NLRP3 inflammasome these lead to decrease cytokine production , aim of study To evaluate whether colchicine is effective in the treatment of COVID-19 cases. And to measure the effectiveness of colchicine in alleviating and controlling pulmonary and extra pulmonary complications of COVID-19
Study Details
Timeline
Interventions
participant will be given a Colchicine regimen in a dose of 0.5mg twice daily for 14 days or until symptoms subsides,those with low body weight and develop side effect like diarrhea and vomiting dose will be reduced and supportive treatment will be given .
control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.